Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.
Eligibility criteria
Qualifiers
Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging (e.g., CT scans), or clinically diagnosed primary aldosteronism patients requiring subtyping
Signed written informed consent, with willingness and ability to comply with study procedures.
Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required.
Male participants must use reliable contraception during the study and refrain from sperm donation.
Disqualifiers
Severe neurological disorders, or any significant diseases affecting the gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, or immune systems, or other serious illnesses.
Diagnosis of claustrophobia.
History of drug abuse or alcohol dependence.
Pregnant or breastfeeding women.
Trial design
Treatments tested in this trial
- Al18F-NOTA-Pentixafor PET/CT
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov